+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 195 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety, optimal dose, and effectiveness of a combination treatment involving BNT323 trastuzumab pamirtecan and BNT327 pumitamig in people with advanced breast cancer. This includes patients with hormone receptor-positive or negative, HER2-positive, HER2-low, HER2-ultralow, HER2-null breast cancer, or triple-negative breast cancer. The study is a Phase III, multi-site, open-label trial designed to find the best dose and assess the treatments effects in these groups. The study has two parts. Part 1 involves dose escalation where participants with chemotherapy-pretreated advanced breast cancer receive various dose levels of BNT323 plus BNT327 to determine the recommended Phase 2 dose. Part 2 includes dose optimization and exploratory groups, beginning after Part 1s completion. In Part 2 Cohort 1, participants are randomized into four arms to receive either the combination at the recommended dose, the combination at another dose, BNT323 alone, or BNT327 alone. Other cohorts receive the recommended dose without randomization. Participants will undergo treatment cycles with intravenous infusions of the study drugs and be monitored for safety, side effects, and tumor response for up to 36 months. Assessments include tracking dose-limiting toxicities, adverse events, tumor scans, and response rates. Safety monitoring continues up to 90 days after the last dose. The study aims to provide detailed information on the best dose, safety, and potential benefits of these treatments for advanced breast cancer.

Age: 18Years +All GendersPhase 1Phase 2
81 locations
G

Actively Recruiting

Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
306 locations
A

Actively Recruiting

Researchers are studying the use of unlicensed cryopreserved cord blood units CBUs for transplantation in both children and adults with blood cancers and other related disorders. This observational study involves patients with hematologic malignancies and various inherited and acquired disorders affecting the blood and immune system. The main goal is to monitor how well neutrophil recovery occurs after transplantation using these unlicensed CBUs in multiple institutions. Participants receive unlicensed cryopreserved CBUs as part of their transplant treatment. The study includes patients of any age receiving these CBUs for approved indications. The protocol focuses on the access and distribution of these unlicensed units rather than a specific treatment intervention. The study gathers data from recipients who receive these CBUs, tracking outcomes after transplantation. Participants are monitored for neutrophil recovery at 60 and 100 days after transplant, defined by a neutrophil count of at least 500mm3. Researchers also collect information on infection transmission, infusion reactions, survival rates at one year, and incidence of acute and chronic graft versus host disease. Platelet recovery is also evaluated. Safety and efficacy outcomes are followed over time to better understand the effects of unlicensed CBUs in this patient population.

All AgesAll Genders
142 locations
P

Actively Recruiting

Researchers are evaluating the safety and tolerability of NKX019, an investigational allogeneic CD19-directed CAR NK cell therapy, in adults with autoimmune diseases such as Lupus Nephritis and Primary Membranous Nephropathy. This Phase 12, open-label, multi-center study uses a dose escalation design to find recommended doses and assess preliminary effects, pharmacokinetics, and pharmacodynamics. Participants undergo a treatment cycle starting with lymphodepletion using fludarabine and cyclophosphamide or cyclophosphamide alone if cytopenic, followed by three doses of NKX019. The study uses a 33 dose escalation to determine safe dosing and includes dose expansion cohorts. The treatment aims to evaluate the impact of NKX019 on autoimmune disease activity and kidney function. During the study, participants are closely monitored for dose-limiting toxicities, adverse events, and lab abnormalities from the first dose until follow-up. Researchers assess kidney response, disease activity scores, and drug levels in blood for up to two years after infusion. Immunogenicity and effects on background therapies are also evaluated. The total participation time varies based on follow-up assessments and treatment response.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
19 locations
R

Actively Recruiting

Researchers are evaluating SUN-627 in adults aged 18 to 70 years who have been diagnosed with non-active Secondary Progressive Multiple Sclerosis SPMS or Primary Progressive Multiple Sclerosis PPMS. This Phase 2a clinical trial aims to study the safety, tolerability, pharmacokinetics, pharmacodynamics, and its effects on neuroinflammation in the central nervous system. The study is designed as a randomized, double-blind, placebo-controlled trial to compare SUN-627 with placebo. Participants will receive SUN-627 or placebo orally once daily at two different dose levels during the treatment period. The study lasts for 16 weeks, with the treatment phase spanning 12 weeks. SUN-627 is administered as an immediate-release tablet, and the placebo matches the oral administration schedule. The trial includes two experimental groups receiving different SUN-627 doses and one placebo group. Throughout the study, participants will be closely monitored for safety by tracking treatment-emergent and serious adverse events. Researchers will also measure SUN-627 concentrations in plasma and changes from baseline in neuroinflammation biomarkers. Participants will undergo assessments during the 12-week treatment and continue under observation until the study concludes at 16 weeks, providing data on the drugs impact and safety profile.

Age: 18Years - 70YearsAll GendersPhase 2
7 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.

Age: 18Years +All GendersPhase 3
318 locations
E

Actively Recruiting

Researchers are studying the effects of AZD0120, an autologous dual-targeting CAR-T therapy aimed at BCMA and CD19, compared with autologous stem cell transplant ASCT in people newly diagnosed with multiple myeloma who are eligible for transplant. This open-label, randomized Phase III trial aims to measure progression-free survival and the rate of minimal residual disease negative complete response over up to 13 years. Participants are assigned to one of two treatment groups. Arm A receives lymphodepletion with cyclophosphamide and fludarabine over three days, followed by a single infusion of AZD0120 CAR-T cells, then up to two years of lenalidomide maintenance therapy. Arm B receives high-dose melphalan conditioning for 24 to 48 hours followed by ASCT and then the same lenalidomide maintenance regimen for up to two years. The study includes a long-term follow-up period lasting up to 15 years after the last AZD0120 infusion. Throughout the study, participants undergo regular monitoring, including assessments of disease progression and response according to established criteria. Researchers evaluate outcomes such as progression-free survival, complete and overall response rates, duration of response, and safety over approximately 13 years. Participants may expect study visits and evaluations aligned with treatment and follow-up schedules to track their health and treatment effects during this extended period.

Age: 18Years - 130YearsAll GendersPhase 3
114 locations
P

Actively Recruiting

Researchers are evaluating the safety and effect of utidelone combined with capecitabine in patients who have HER2-negative breast cancer that has spread to the brain. This Phase II trial aims to assess how well utidelone alone or together with capecitabine works to control tumors inside the brain and elsewhere in the body for these patients. Participants will receive utidelone intravenously once daily for five days every 21 days, either alone or combined with capecitabine taken orally twice daily for up to 14 days in a 21-day cycle. The study includes two stages with different groups receiving either monotherapy or combination treatments to compare outcomes. During the trial, participants will undergo regular brain MRI scans and other assessments to measure tumor response using RECIST 1.1 and RANO-BM criteria over 12 months. Researchers will monitor progression-free survival, overall survival up to 24 months, and treatment-related side effects. The study requires participants to attend visits for evaluations and follow-up testing throughout the treatment and observation periods.

Age: 18Years +All GendersPhase 2
12 locations
P

Actively Recruiting

Researchers are studying an investigational drug called linvoseltamab in adults who have a moderate risk of developing multiple myeloma. This group includes patients with precancerous conditions known as High-Risk Monoclonal Gammopathy of Undetermined Significance HR-MGUS and Non-High-Risk Smoldering Multiple Myeloma NHR-SMM. The main goal is to understand how well linvoseltamab can eliminate abnormal plasma cells and laboratory signs associated with these conditions. Participants will receive linvoseltamab following a step-up dosing regimen to assess safety and tolerability before moving to one of four full dosing regimens. The study is divided into a safety run-in phase and an expansion phase where participants are assigned to different dose groups without randomization. Linvoseltamab is given according to the study protocol, with dosing schedules designed to monitor effects and side effects. During the study, participants will be closely monitored through regular safety observations over 35 days and longer-term assessments up to 5.5 years. Researchers will track adverse events, treatment responses including complete response rates, laboratory results, and the presence of antibodies against the drug. Blood levels of linvoseltamab are measured up to 9 months. This comprehensive monitoring will help understand the drugs impact and safety over time.

Age: 18Years +All GendersPhase 2
39 locations

1-10 of 195

1